More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
How can healthcare balance the pros and cons consumers see when they think about all the data being collected on them?
Well, the data is out there. I think there is a sense of the public trust having been violated and at the same time everybody acknowledges—I’ve got a lot of friends, especially younger generation, like “Yeah, they collect it and I don’t care. I have Alexa and I have Google in my home, and I know they’re collecting data on me and I don’t care.”
So, is healthcare data really any different? Or is the fact that we’re using social data that we can get on a patient to improve the care that we’re delivering, is that a bad thing? Or is that a good thing? That’s the kind of question that should be raised and debated, but in general, one of the guiding principles there is beneficence, and the good intention behind having that data in order to render better care is certainly noble.
So, at the end of the day, in healthcare, I think we win the ethical discussion and we are certainly in a better position than say the big industry tech giants that are using it for profit.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More